Evoke Pharma (EVOK) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evoke Pharma Reports First Quarter 2018 Results and Highlights
May 14, 2018 6:30 AM EDTNDA submission for Gimoti on track for second quarter of 2018Announced discovery of sex-based pharmacokinetic differences for GimotiWaiver of the PDUFA fee for Gimoti NDA granted by FDACash runway extended into April 2019
SOLANA BEACH, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2018.
Dave Gonyer, R.Ph., President and CEO, stated, After successfully completing our comparative exposure... More
